Key result
Multimodal lipid lowering cuts LDL-C ~85% at 3 months in familial combined hyperlipidemia.
Why the study?
Familial combined hyperlipidemia is often underdiagnosed and may silently progress to severe coronary disease leading to sudden cardiac arrest in young adults.
Case Report (n=1)
Familial combined hyperlipidemia can silently progress to severe coronary artery disease and initially present as sudden cardiac arrest in young adults, highlighting the critical need for early identification and aggressive lipid management.
Supports lipid screening post-arrest in young adults; leaves open FCHL-specific arrhythmia risk stratification.
BACKGROUND: Familial combined hyperlipidemia (FCHL) affects 0.5% to 2% of the population and is a significant risk factor for premature myocardial infarction, accounting for up to 16% of cases. CASE SUMMARY: A 46-year-old man experienced cardiac arrest while surfing. Emergency services found him pulseless with ventricular fibrillation requiring 2 defibrillations and 10 minutes of resuscitation before return of spontaneous circulation. Bloodwork revealed severe dyslipidemia (low-density lipoprotein cholesterol 358 mg/dL, triglycerides 1,622 mg/dL) consistent with FCHL. Coronary angiography demonstrated triple-vessel disease, requiring coronary artery bypass grafting. He received multimodal lipid-lowering therapy and subcutaneous implantable cardioverter-defibrillator. At 3 months, there was dramatic improvement in dyslipidemia (low-density lipoprotein cholesterol 52 mg/dL, triglycerides 232 mg/dL). DISCUSSION: FCHL is often underdiagnosed due to lack of routine genetic screening and may silently progress to severe coronary disease. TAKE-HOME MESSAGES: Consider FCHL in young adults with sudden cardiac arrest or premature coronary disease. Early identification, aggressive therapy, and familial screening are crucial.
No takes yet. Share an insight, caveat, or question.
Pelletier et al. (2026) conducted a case report in Familial Combined Hyperlipidemia and Sudden Cardiac Arrest (n=1). Multimodal lipid-lowering therapy, CABG, and subcutaneous ICD was evaluated on Improvement in dyslipidemia (LDL cholesterol and triglycerides). Multimodal lipid-lowering therapy improved LDL-C (358 to 52 mg/dL) and triglycerides (1622 to 232 mg/dL) at 3 months in a 46-year-old man presenting with FCHL and sudden cardiac arrest.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: